"biotechs require much more stringent for obvious reasons - to meet guidelines and regulations"
Hasn't prevented Alnylam from attaining an @ $2billion market cap. Their efficiency and durabilty is questionable to say the least.
- Forums
- ASX - By Stock
- BLT
- capital raising !